A new drug called Survodutide, which is a dual glucagon-like peptide 1 (GLP-1) and glucagon receptor agonist, has shown exceptional improvement in patients with metabolic dysfunction-associated steatohepatitis (MASH) based on phase 2 trial results. Up to 83% of patients on Survodutide experienced significant improvement in MASH compared to those on a placebo. Additionally, 75% of patients treated with Survodutide had resolution of MASH without worsening of fibrosis. The drug also showed promising results in reducing liver fat, improving fibrosis, and metabolic function. Survodutide is currently being investigated in phase 3 studies for overweight and obesity, conditions associated with MASH.
Source link
‘Dramatic’ Phase 2 Results for Survodutide in MASH, Fibrosis
